India Rejects Patent Application for Shorter Drug-Resistant TB Treatment

The Indian patent office has rejected an application for a shorter drug-resistant tuberculosis treatment regimen. This decision aims to facilitate greater generic competition within the pharmaceutical market. Experts believe the move could significantly lower treatment costs, though the ultimate impact depends on drug availability, pricing strategies, and improved access to patient care.